|Table of Contents|

Efficacy and safety of anlotinib in maintenance therapy of advanced biliary tract cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 17
Page:
3232-3236
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of anlotinib in maintenance therapy of advanced biliary tract cancer
Author(s):
WANG Ran; YU Yuandong
Department of Oncology,Shiyan People's Hospital Affiliated to Hubei University of Medicine,Hubei Shiyan 442000,China.
Keywords:
biliary tract cancer; anlotinib; maintenance therapy
PACS:
R735.8
DOI:
10.3969/j.issn.1672-4992.2023.17.016
Abstract:
Objective:To assess the efficacy and safety of anlotinib in maintenance therapy of advanced biliary tract cancer(BTC).Methods:From September 2020 to September 2021,42 patients with advanced biliary carcinoma who had achieved complete response,partial response or stable disease after first-line chemotherapy in the Department of Oncology,Shiyan People's Hospital of Hubei Province were enrolled.They were treated with anlotinib 3 weeks after the end of first-line chemotherapy until disease progression.The primary endpoints were ORR and DCR,and the secondary endpoints were PFS,1-year overall survival rate and safety of anlotinib administration.Results:39 patients could be evaluated according to RECIST 1.1 criteria,9 patients had a partial response,12 had stable disease,and no patients with a complete responses.The ORR was 23.08%,DCR was 53.85%,mPFS reached 6.0 months(4.997~7.003),and the 1-year overall survival rate was 69.2%.82.05% of the patients reported adverse events,the main adverse events were hypertension,hand and foot skin reaction,no grade 4 or higher adverse events occurred,no patients discontinued the drug because of adverse events.Conclusion:Anlotinib demonstrates potential efficacy and tolerable safety in themaintenance therapy for patients with advanced BTC after first-line chemotherapy,and studies with larger sample size are needed to further confirm.

References:

[1]ROTH GA,ABATE D,ABATE KH,et al.Global,regional,and national age-sex-specific mortality for 282 causes of death in 195 countries and territories,1980-2017:a systematic analysis for the Global Burden of Disease Study 2017［J］.The Lancet,2018,392(10159):1736-1788.
[2]PARK JO,OH DY,HSU C,et al.Gemcitabine plus cisplatin for advanced biliary tract cancer:A systematic review［J］.Cancer Res Treat,2015,47(3):343-361.
[3]TARIQ NU,MCNAMARA MG,VALLE JW.Biliary tract cancers:current knowledge,clinical candidates and future challenges［J］.Cancer Manag Res,2019,11:2623-2642.
[4]VALLE J,WASAN H,PALMER DH,et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］.N Engl J Med,2010,362(14):1273-1281.
[5]LAMARCA A,PALMER DH,WASAN HS,et al.Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer(ABC-06):a phase 3,open-label,randomised,controlled trial［J］.Lancet Oncol,2021,22(5):690-701.
[6]LAMARCA A,BARRIUSO J,MCNAMARA MG,et al.Molecular targeted therapies:Ready for "prime time" in biliary tract cancer［J］.J Hepatol,2020,73(1):170-185.
[7]GOYAL L,SAHA SK,LIU LY,et al.Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma［J］.Cancer Discov,2017,7(3):252-263.
[8]GRAHAM RP,BARR FE,PESTOVA E,et al.Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma［J］.Hum Pathol,2014,45(8):1630-1638.
[9]CHURI CR,SHROFF R,WANG Y,et al.Mutation profiling in cholangiocarcinoma:prognostic and therapeutic implications［J］.PLoS One,2014,9(12):e115383.
[10]VALLE JW,LAMARCA A,GOYAL L,et al.New horizons for precision medicine in biliary tract cancers［J］.Cancer Discov,2017,7(9):943-962.
[11]XIE C,WAN X,QUAN H,et al.Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor［J］.Cancer Sci,2018,109(4):1207-1219.
[12]SHEN G,ZHENG F,REN D,et al.Anlotinib:a novel multi-targeting tyrosine kinase inhibitor in clinical development［J］.J Hematol Oncol,2018,11(1):120.
[13]HAN B,LI K,WANG Q,et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018,4(11):1569-1575.
[14]SUN Y,NIU W,DU F,et al.Safety,pharmacokinetics,and antitumor properties of anlotinib,an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors［J］.J Hematol Oncol,2016,9(1):105.
[15]YUAN J,CHENG F,XIAO G,et al.Efficacy and safety of anlotinib in the treatment of small cell lung cancer:A real-world observation study［J］.Front Oncol,2022,12:917089.
[16]ALI AH,TABIBIAN JH,NASSER-GHODSI N,et al.Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis［J］.Hepatology,2018,67(6):2338-2351.
[17]RIZVI S,GORES GJ.Pathogenesis,diagnosis,and management of cholangiocarcinoma［J］.Gastroenterology,2013,145(6):1215-1229.
[18]XIE N,CAI JB,ZHANG L,et al.Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma［J］.Cell Death Dis,2017,8(12):3205.
[19]SHROFF RT,JAVLE MM,XIAO L,et al.Gemcitabine,cisplatin,and nab-paclitaxel for the treatment of advanced biliary tract cancers:A phase 2 clinical trial［J］.JAMA Oncol,2019,5(6):824-830.
[20]VALLE JW,KELLEY RK,NERVI B,et al.Biliary tract cancer［J］.Lancet,2021,397(10272):428-444.
[21]KAM AE,MASOOD A,SHROFF RT.Current and emerging therapies for advanced biliary tract cancers［J］.Lancet Gastroenterol Hepatol,2021,6(11):956-969.
[22]DO-YOUN OH,AIWU RUTH HE,SHUKUI QIN,et al.A phase 3 randomized,double-blind,placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin(GemCis) in patients(pts) with advanced biliary tract cancer(BTC):TOPAZ-1［J］.Journal of Clinical Oncology,2022,40(4_suppl):378-378.
[23]ZHOU J,SUN Y,ZHANG W,et al.Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis［J］.Hepatology,2023,77(1):65-76.
[24]UENO M,IKEDA M,SASAKI T,et al.Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer:primary analysis results［J］.BMC Cancer,2020,20(1):1105.
[25]WANG Y,YANG X,WANG D,et al.Lenvatinib beyond first-line therapy in patients with advanced biliary tract carcinoma［J］.Front Oncol,2022,12:785535.
[26]DEMOLS A,BORBATH I,VAN DEN EYNDE M,et al.Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors:REACHIN,a randomized,double-blind,phase II trial［J］.Ann Oncol,2020,31(9):1169-1177.
[27]FARSHIDFAR F,ZHENG S,GINGRAS MC,et al.Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles［J］.Cell Rep,2017,18(11):2780-2794.
[28]LEI H,DENG CX.Fibroblast growth factor receptor 2 signaling in breast cancer［J］.Int J Biol Sci,2017,13(9):1163-1171.
[29]ABOU-ALFA GK,SAHAI V,HOLLEBECQUE A,et al.Pemigatinib for previously treated,locally advanced or metastatic cholangiocarcinoma:a multicentre,open-label,phase 2 study［J］.Lancet Oncol,2020,21(5):671-684.
[30]LIN B,SONG X,YANG D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRbeta and FGFR1［J］.Gene,2018,654:77-86.
[31]HYUNG J,KIM B,YOO C,et al.Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin［J］.Cancer Res Treat,2019,51(3):901-909.

Memo

Memo:
-
Last Update: 2023-07-31